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INTRODUCTION
Neuroendocrine tumors of the pancreas are rare neoplasms representing  approximately 2% of all pancreatic tumors9. Due to the progress of 
diagnostic imaging and radioimmunoassay, its diagnosis 
has become more frequent. Recent epidemiological studies 
suggest increased frequency12. Among the functioning 
tumors, vipoma (tumor cells producing vasoactive intestinal 
polypeptide) is also known as WDHA syndrome (watery 
diarrhea, hypokalaemia, and achlorhydria), Werner Morrison´s 
syndrome and pancreatic cholera; it is still rare neoplasia, 
mainly characterized by profuse diarrhea with hydro-
electrolytic disorders. It has an estimated incidence of 0,2 to 
0,5 per million inhabitants per year3. Approximately 90% of 
these tumors originate in the pancreas; however, there are 
descriptions located in other segments of the gastrointestinal 
tract, bronchus, adrenal, sympathetic ganglia and liver. There 
are few cases described in the medical literature of extra-
pancreatic location in adults8. Due to its low incidence, it 
is unknown the true epidemiological data of this unique 
neoplasm. 
The objective of this report is to present another case of 
extra-pancreatic vipoma.
CASE REPORT
Man of 54 years old had for four months diarrhea, watery 
stools, often in every three hours lasting 15 days; had 14 kg 
weight loss during this period, with asthenia, anorexia, malaise, 
muscle weakness and cramps. Laboratory tests showed VIP 
(intestinal polypeptide active vessel) 242 pg/ml (<75); Na=138; 
K=1.6; and  creatinine=1.53. Ultrasonography showed 
hypoechoic image on segment IV of 4.2 cm, confirmed by 
CT with the presence of several hypervascular images in liver 
segments IV, III, II (Figure 1). Ultrasonography guided biopsy 
was performed in one liver nodule that revealed metastatic 
neuroendocrine carcinoma by immunohistochemistry. 
Laparotomy confirmed multiple liver metastases (Figure 2). 
Intraoperative ultrasonography showed nodule in pancreatic 
body. Bodycaudal pancreatectomy with splenectomy (Figure 
3) and left hepatic trisegmentectomy were performed (Figure 
4). No tumor was found in the pancreatic parenchyma. 
Histopathology showed acinar atrophy and hyperplasia of 
islets in the caudal region. In peri-pancreatic adipose tissue was 
confirmed the presence of five nodes with well-differentiated 
neuroendocrine carcinoma infiltrating the adipose tissue 
adjacent the neoplastic infiltration beyond perineural and 
angiolymphatic (Figure 5). Hepatic lesions confirmed the 
diagnosis of metastatic well-differentiated neuroendocrine 
carcinoma. Immunohistochemical analysis showed positivity 
for sinaftofisin, chromogranin and intestinal polypeptide active 
vessel (VIP). Ki-67 was positive in 10%. Patient had no major 
complications. There was immediate regression of diarrhea 
and electrolyte abnormalities. After 12 months, returned again 
with the same initial clinical picture. Liver CT images showed 
multiple metastatic nodulation diffusely distributed. Therapy 
with somatostatin analogue with prolonged action (LAR) 
and chemotherapy with inhibitors of mTOR (everolimus) was 
started with regression of liver lesions and clinical symptoms. 
At the third year postoperatively he was without clinical signs 
of disease recurrence.
DISCUSSION
Although there is a previous report, this neoplasm was first 
described by Werner and Morrison in 1958 in two patients with 
profuse diarrhea and hypokalemia associated with malignancy 
of non insulin-producing pancreatic islets. Its pathophysiological 
aspects were more well-known since 1973, the time in which 
Bloom et al.2 associated WDHA syndrome with increased 
serum vasoactive intestinal polypeptide5, a fact later confirmed 
by the studies of Kane et al.7 reproducing this syndrome after 
intravenous administration of VIP in five volunteers6. It is an 
aminoacid peptide produced by the delta-2 pancreatic islet cells 
and is also present in the central and peripheral nervous system 
and considered as a neurotransmitter. High concentrations are 
found in the gastrointestinal tract. Among its effects are described: 
stimulation of the smooth muscles of the gastrointestinal tract; 
increasing intestinal and pancreatic secretions; vasodilation; 
inhibition of gastric acid secretion; increased glycogenolysis 
and hypercalcemia4. Classically, vipomas present profuse 
diarrhea with consequent electrolyte repercussions, weight 
loss, and, more rarely, skin lesions, tachycardia and low back 
pain. Relatively often, these patients are initially investigated by 
a number of more common diseases whose main symptom is 
diarrhea. Much of this neoplasm originates in the pancreas and 
is sporadic; but may also be associated with multiple endocrine 
neoplasia11. However, these tumors can arise in the ganglia of 
the sympathetic nervous system, especially in children. Extra-
pancreatic vipomas can be classified by their origin in neurogenic 
and non-neurogenic, the latter very little reported in literature5. 
From the clinical, laboratory and histopathological findings, it is 
not possible to differentiate neurogenic extra-pancreatic tumors. 
The neurogenic appears to have less severe clinical picture, lower 
VIP levels when compared to gastrointestinal disturbances, lack 
of production of pancreatic polypeptide and histopathological 
different characteristics8. The clinical diagnosis is confirmed by 
the increase in the level of serum VIP and radiological findings, 
mostly performed by computed tomography or magnetic 
resonance, localizing the tumor in the pancreas topography in 
most cases, due to the fact that most of these tumors have more 
than 3 cm. Likewise, more than 60% of these tumors have liver or 
lymph node metastasis at the time of diagnosis1. The therapeutic 
approach is to initially control the electrolyte disturbances, use 
of somatostatin analogues and subsequently surgical approach. 
Similar to others gastroenteroneuroendocrine diseases, also 
to other cancers, surgical resection is the best way to control 
the clinical symptoms and prolong survival10; it also can be 
performed cytoreductive operation, resection of liver metastases 
and even liver transplantation. The completion of adjuvant 
chemotherapy appears to play an important role in controlling 
the disease and have been described in addition to biotherapy 
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with somatostatin analogues for long-term use to increase 
survival with good quality of life6,9. In this patient, besides the 
surgical treatment of liver metastases and the recurrence of the 
disease, there was considerable gain in life expectancy with the 
use of adjuvant chemotherapy. 
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INTRODUCTION
The primary retroperitoneal cystadenoma is very rare tumor, described by Handfield-Jones in 1924 and observed almost exclusively in women1. The 
symptoms are usually nonspecific, hampering its differential 
diagnosis with other retroperitoneal masses and makes 
them with imaging and surgical approach for diagnosis and 
treatment2. 
The present report is of one case of a primary benign 
retroperitoneal mucinous cystadenoma.
CASE REPORT
Woman 51 year old referred abdominal pain since 
one year ago, located on the right flank and radiating to 
the lumbar region, with progressive worsening. Physical 
examination revealed a palpable mass in the right flank, 
painless. Was submitted  to ultrasound examination which 
identified a bulky abdominal cystic lesion. Computed 
tomography (Figures 1 and 2) revealed homogeneous 
retroperitoneal cystic lesion measuring 15x12, 5x5, 5 cm 
and medially displacing the ascending colon, suggesting 
the diagnosis of cystic lymphangioma. The patient 
underwent exploratory laparotomy (Figures 3 and 4), 
which identified massive retroperitoneal cystic lesion 
which was dissected from adjacent structures with ease, 
allowing complete resection. The pancreas and ovaries 
showed no alterations or contiguity with the injury. No 
complications were observed during the postoperative 
course. Pathological examination of the surgical specimen 
revealed retroperitoneal mucinous cystadenoma benign 
(Figures 5 and 6).
FIGURE 1 - Computed tomography of the abdomen:  shows 
a cystic image of regular walls without mural 
nodules or vegetations
FIGURE 2 - Computed tomography of the abdomen: shows 
massive retroperitoneal cystic lesion occupying 
the right flank and iliac fossa
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